FDA On Drug Pricing: Incremental Steps, But No Full-Frontal Assault
Executive Summary
US agency will continue to avoid ‘big bold’ actions on drug pricing under the Trump Administration, industry representatives and attorneys predict, adding that easing restrictions on manufacturer communications to payers and advocating for biosimilars would help in pricing debate.
You may also be interested in...
The Latest Furor Over Trump’s Drug Pricing Plan
Did the head of the Office and Management & Budget really endorse Part D rebates? Like so much about the Trump Administration’s response to drug pricing, there is probably a lot less to the story than it sounds.
User Fee Bill Caught In Comey Firing Tidal Wave
Senate committee forced to postpone mark-up of FDA user fee reauthorization legislation; drug pricing fight may be postponed by hearing pledge.
User Fee Bill Caught In Comey Firing Tidal Wave
Senate committee forced to postpone mark-up of FDA user fee reauthorization legislation; drug pricing fight may be postponed by hearing pledge.